artesunate/sulfadoxine/pyrimethamine

{{Infobox drug

| drug_name =

| type = combo

| component1 = Artesunate

| class1 = Antimalarial

| component2 = Sulfadoxine

| class2 = Sulfonamide antimalarial

| component3 = Pyrimethamine

| class3 = Antimalarial

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category=

| routes_of_administration =

| ATCvet =

| ATC_prefix =

| ATC_suffix =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US =

| legal_US_comment =

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| CAS_number =

| PubChem =

| DrugBank =

| KEGG =

}}

Artesunate/sulfadoxine/pyrimethamine is an artesunate-based oral medication used to treat malaria.{{cite journal | vauthors = Arya A, Kojom Foko LP, Chaudhry S, Sharma A, Singh V | title = Artemisinin-based combination therapy (ACT) and drug resistance molecular markers: A systematic review of clinical studies from two malaria endemic regions - India and sub-Saharan Africa | journal = International Journal for Parasitology: Drugs and Drug Resistance | volume = 15 | issue = | pages = 43–56 | date = April 2021 | pmid = 33556786 | pmc = 7887327 | doi = 10.1016/j.ijpddr.2020.11.006 }} It consists of artesunate and sulfadoxine/pyrimethamine.{{cite journal |title=Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria (ASPF) |website=clinicaltrials.gov |publisher=University of Oxford |date=July 11, 2012 |url=https://clinicaltrials.gov/ct2/show/NCT01115439 |access-date=June 6, 2017}}